These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29382267)

  • 1. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2018 Jan; 107(3):167-168. PubMed ID: 29382267
    [No Abstract]   [Full Text] [Related]  

  • 2. [Not Available].
    Själander S; Själander A
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
    [No Abstract]   [Full Text] [Related]  

  • 3. Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
    Eek AK; Øie E; Granas AG
    Eur J Clin Pharmacol; 2018 Mar; 74(3):323-330. PubMed ID: 29149366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New oral anticoagulants in patients with atrial fibrillation in a urban health center].
    Rodríguez Pérez L; Capilla Lozano F; Gallego Fuentes R; Buitrago F
    Med Clin (Barc); 2016 Mar; 146(6):280-1. PubMed ID: 26343157
    [No Abstract]   [Full Text] [Related]  

  • 5. Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism.
    Robert-Ebadi H; Righini M
    Ther Umsch; 2016; 73(10):618-625. PubMed ID: 28045360
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
    Khorana AA; Noble S; Lee AYY; Soff G; Meyer G; O'Connell C; Carrier M
    J Thromb Haemost; 2018 Sep; 16(9):1891-1894. PubMed ID: 30027649
    [No Abstract]   [Full Text] [Related]  

  • 7. The new oral anticoagulants: Reasonable alternatives to warfarin.
    Roca B; Roca M
    Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Grübler B
    Hamostaseologie; 2018 Feb; 38(1):58-59. PubMed ID: 29536484
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral Anticoagulants.
    Pollack CV
    Circulation; 2016 Jan; 133(2):e18-9. PubMed ID: 27028439
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous thrombolysis for stroke in patients taking non-VKA oral anticoagulants: an update.
    Cappellari M; Bovi P
    Thromb Haemost; 2015 Aug; 114(2):440-4. PubMed ID: 25809649
    [No Abstract]   [Full Text] [Related]  

  • 11. Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.
    Krumme AA; Pawar A; Schneeweiss S; Glynn RJ; Choudhry NK; Kulldorff M; Ortiz AS; Avorn J; Gagne JJ
    J Comp Eff Res; 2018 Jan; 7(1):57-66. PubMed ID: 29264930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
    Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
    Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic Therapy for Venous Thromboembolic Disease.
    Jain A; Cifu AS
    JAMA; 2017 May; 317(19):2008-2009. PubMed ID: 28510665
    [No Abstract]   [Full Text] [Related]  

  • 15. Apixaban (Eliquis) in deep vein thrombosis and pulmonary embolism. Warfarin remains the standard therapy.
    Prescrire Int; 2015 Sep; 24(163):206. PubMed ID: 26417627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
    Steed MB; Swanson MT
    Oral Maxillofac Surg Clin North Am; 2016 Nov; 28(4):515-521. PubMed ID: 27624772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Security profile of direct anticoagulants. Preferred use in atrial fibrillation.
    Roldán Rabadán I; Alonso de Leciñana M; Barba Martín R; Páramo Fernández JA;
    Clin Investig Arterioscler; 2019; 31(6):263-270. PubMed ID: 31213323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended use of sulodexide, apixaban, rivaroxaban and dabigatran in venous thromboembolism: indirect comparison of clinical trials.
    Tomkowski W; Kuca P; Bignamini AA; Andreozzi GM
    Int Angiol; 2017 Oct; 36(5):496-497. PubMed ID: 28641408
    [No Abstract]   [Full Text] [Related]  

  • 19. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2018 Jan; 107(1):45-46. PubMed ID: 29295673
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.